ORIGYN-FOUNDATION
22.4.2022 18:16:12 CEST | Business Wire | Press release
ORIGYN Foundation, the Swiss non-profit foundation dedicated to identifying, authenticating and unlocking the powers of ownership for objects of value, has announced a partnership with UEFA Foundation for Children. ORIGYN and the UEFA Foundation for Children will partner to create a unique selection of collectibles and NFTs that directly benefits the foundation’s mission to fund children’s rights in areas such as health, education and integration.
As a key component of ORIGYN’s ‘NFTs for Good’ initiative, ORIGYN and UEFA Foundation for Children will create a limited collection of physical collectibles. A corresponding digital twin will be created for each of the one-of-a-kind memorabilia, including one of the toss coins that helped determine the outcome of the UEFA EURO 2020 Final between England and Italy.
“We are thrilled to partner with ORIGYN to bring these important items to the world stage and for the benefit of The UEFA Foundation for Children,” said Urs Kluser, General Secretary for the UEFA Foundation for Children. “We share a united vision of leveraging next-generation technology such as NFTs to raise money for children and world citizens across the globe. There is no better collective mission.”
ORIGYN is the only platform that ties the digital certificate to the world’s most valuable physical artifacts and collectibles. These digital twins are non-fungible, unique and, in many cases, tied to a corresponding physical object. The iconic coin will be minted by ORIGYN into a digital twin NFT and auctioned off together with the physical coin in the second quarter of 2022, alongside other rare collectibles from the foundation.
“We’re incredibly fortunate to have partnered with a foundation that shares a passion for helping children around the world. NFTs are a global technology and should benefit all,” said Daniel Haudenschild , CEO of ORIGYN Enterprise.
This series of unique sports collectibles from the UEFA Foundation for Children, as well as their corresponding digital twin NFTs, will exclusively appear on the ORIGYN-powered consumer marketplace, Impossible Things. Impossible Things will allow collectors to buy, sell and experience unique and authenticated collectibles.
The Impossible Things marketplace will launch in Q2 of 2022 with an Impossible Pass, providing holders priority access to all of the limited collection drops to appear on the marketplace.
“Leveraging ORIGYN’s proprietary technology and the unique consumer-friendly platform at Impossible Things enables us to support causes like The UEFA Foundation for Children, as well as collectors and investors who demand authenticity from the goods they purchase and the cultures that surround them,” said Tom Flanagan, Managing Director of ORIGYN Collectibles.
About the ORIGYN Foundation:
The Swiss non-profit foundation ORIGYN uses intelligent technologies, including computer vision and artificial intelligence, on decentralized computing to identify, authenticate and unlock the powers of ownership for objects of value. As the first digital certification platform built on the Internet Computer (IC), ORIGYN and its verticals generate new forms of value for some of the largest consumer asset classes in the world, including art, collectibles, digital media and luxury goods. Founded in Neuchâtel, Switzerland in October of 2020, ORIGYN operates globally in major technology and blockchain hubs around the world. The foundation’s utility token, OGY, is set to become publicly tradable in the second quarter of 2022. For more information, visit origyn.ch .
ORIGYN Foundation: Website Twitter Telegram LinkedIn Facebook Medium Instagram
For more information about Impossible Things, visit here .
About The UEFA Foundation for Children:
The UEFA Foundation for Children aims to help children and defend their rights, for example through sport and football. It provides support in the areas of health, education, access to sport, personal development, integration of minorities and employability. The Foundation, a public utility body under Swiss law, was created and started its activities on April 24, 2015. The foundation currently invests in 180 projects and has so far funded more than 400 projects in 130 countries worldwide. More than 1.8 million children have already benefited from the foundation's work since its creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220422005488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom